Lenacapavir and the shift to NRTI-free, long-acting HIV treatment: implications for HBV patients
A five-star bake. Worth schmearing, sharing, saving.
Summary
The article discusses the evolving HIV treatment landscape, focusing on the shift toward NRTI-free dual regimens and long-acting injectable formulations. It highlights lenacapavir's potential implications for people living with HBV (hepatitis B virus), noting that new prevention strategies are being deployed at scale with injectable agents that function similarly to vaccine programs, addressing adherence challenges and stigma associated with daily oral therapy.
Key quotes
· 3 pulledAn exciting shift is underway in progress towards tackling HIV as a global public health threat, as we enter a new era of nucleotide and nucleoside reverse transcriptase inhibitor (NRTI)-free dual regimens and long-acting injectable formulations for both treatment and prevention.
HIV prevention strategies are now being actively deployed at scale, with injectable long-acting agents that are functionally similar to a vaccine programme.
New options that tackle adherence challenges and potential stigma associated with daily oral therapy.
You might also wanna read
FDA Approves First 100% Effective HIV Prevention Drug with Global Impact
The article discusses the milestone approval of the first HIV prevention drug, lenacapavir (brand name Yeztugo), which offers 100% protectio
newatlas.com·10mo agoEfficient mRNA delivery to resting T cells to reverse HIV latency
Columbia Researcher Discovers Rare Genetic Mutation That Provides Universal Antiviral Immunity
Columbia University immunologist Dusan Bogunovic discovered that a rare genetic mutation causing immune deficiency in some patients also gra
cuimc.columbia.edu·9mo ago
Children May Hold the Key to a Widespread HIV Cure, Research Suggests
The article explores the groundbreaking research led by Philip Goulder, a pediatrician and immunologist at the University of Oxford, focusin
wired.com·10mo agoAsk HN: What is the latest on treatment of Metastatic Breast Cancer?
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
FDA·1mo ago